Ethyl 3,5-Dimethyl-2-Pyrrolecarboxylate

Manufacture of the non-opioid analgesic ketorolac tromethamine—widely used for short-term management of moderate to severe post-operative pain and listed on the WHO Model List of Essential Medicines—depends on a pyrrole ester intermediate whose 3,5-dimethyl substitution pattern dictates the steric and electronic profile of the final pyrrolo[1,2-b]pyridazine ring system. In a multi-tonne campaign executed in a 2000 L glass-lined reactor equipped with retreat-curve impeller agitation and jacket cooling capability down to −15 °C, ethyl 3,5-dimethyl-2-pyrrolecarboxylate is dissolved in anhydrous dimethylformamide (Karl Fischer < 100 ppm H₂O) and subjected to electrophilic substitution at the unsubstituted 5-position. The charge ratio of the pyrrole ester to p-toluenesulfonyl chloride is maintained at 1.0 : 1.03 to compensate for moisture-induced decomposition of the sulfonyl chloride, and the DMF solution is pre-cooled to 0–5 °C under a dry nitrogen sweep. Dosing the acylating agent over 3.5–4 h with continuous jacket brine circulation at −10 °C absorbs the reaction exotherm—typically peaking at 320 W/kg—and prevents the internal temperature from exceeding 7 °C. Plant-scale deviation data show that excursions above 12 °C trigger decarboxylation of the activated ester, yielding 2,5-dimethylpyrrole as a process impurity detectable by GC-MS at levels above 0.15%; multiple such excursions in a single batch routinely push the impurity budget beyond the 0.10% acceptance criterion required for downstream cyclisation. After 6 h of controlled reaction the mass is quenched into ice-water, the precipitated intermediate isolated on a pressure nutsche, and the wet cake displacement-washed with chilled methanol to strip residual DMF. The dried ketorolac intermediate meets the residual solvent specification of USP <467> and proceeds to the methylhydrazine-driven ring closure under current Good Manufacturing Practice aligned with ICH Q7. The terminal dosage form is a sterile 15 mg/mL injection solution manufactured against the ketorolac tromethamine USP monograph and filled into amber vials for intramuscular or intravenous administration in acute pain protocols.

What Drives the Regioselective Acylation of Pyrrole-2-carboxylates for Arylacetic Acid NSAIDs?

Synthesis of tolmetin sodium—a heteroarylacetic acid NSAID indicated for rheumatoid arthritis and osteoarthritis—exposes a different regiochemical demand on ethyl 3,5-dimethyl-2-pyrrolecarboxylate: the nitrogen must be methylated prior to Friedel-Crafts acylation to block competing N-acylation and to match the pharmacophore requirements of the cyclooxygenase binding pocket. The ester is first treated with methyl iodide (1.2 eq.) and ground potassium carbonate in dimethyl sulfoxide at 30 °C, a step that reaches completion within 5 h in a 500 L Hastelloy C-22 reactor because the methyl iodide charge and the liberated iodide salts necessitate resistance to halide pitting. Following aqueous workup and vacuum distillation, the N-methylated pyrrole ester is dissolved in tetrahydrofuran and reacted with p-toluoyl chloride at a molar ratio of 1.0 : 1.05, the slight excess compensating for adventitious water ingress during the solvent transfer. Isothermal titration calorimetry data gathered via Mettler Toledo RC1mx in process safety laboratories have recorded a heat of reaction of −165 kJ/mol, requiring the acid chloride to be metered over 4 h while maintaining a bulk temperature of 20–25 °C; the reactor is equipped with a back-up kill charge of aqueous sodium bicarbonate that is automatically triggered if the temperature derivative exceeds 0.5 °C/min. The resultant pyrrole amide is then hydrolysed under strongly alkaline conditions (pH 12.3 ± 0.2) at 90 °C for 8 h, and the carboxylate salt is acidified with dilute hydrochloric acid to precipitate the free acid. Tight supervision of the hydrolysis pH window is critical—dropping below pH 11.8 prematurely leaves unreacted amide, whereas overshooting above pH 12.8 promotes decarboxylation that forms the pharmacologically inactive 1,2,5-trimethylpyrrole by-product. The crude tolmetin acid is recrystallized from ethanol/water (7:3 v/v) to yield the sodium salt dihydrate conforming to the Ph.Eur. monograph, residual solvents controlled to ICH Q3C limits, and subsequently filled into hard gelatin capsules 200 mg under FDA 21 CFR Part 211 conditions for oral anti-inflammatory therapy.

A consolidated overview of critical process metrics and regulatory touchpoints across the five manufacturing routes is provided in Table 1.

Photostability requirements in clinical immunoassay dye conjugates force a departure from cyanine-based chromophores, steering synthesis toward 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes built from ethyl 3,5-dimethyl-2-pyrrolecarboxylate. The ester first undergoes controlled partial reduction to the corresponding pyrrole-2-carboxaldehyde with diisobutylaluminium hydride (1.05 eq. in toluene at −70 °C), a cryogenic step demanding a jacketed reactor with liquid nitrogen cooling on pilot scale; any warming above −55 °C during the addition promotes over-reduction to the alcohol, which must be removed by flash chromatography before the condensation step. The crude aldehyde is immediately self-condensed via acid catalysis (trifluoroacetic acid, 0.1 eq.) in boiling toluene with azeotropic water removal; after 3 h the dipyrromethene intermediate is complexed with boron trifluoride diethyl etherate (2.5 eq.) in dichloromethane at 30 °C. Purification on neutral alumina (activity III, column loading 1:50 w/w) separates the target BODIPY dye from non-fluorescent oligomers. The stoichiometry of the aldehyde self-condensation is formally 1:1, but isolated yields from the ethyl ester rarely exceed 55% because pyrrole air-oxidation sidelines become significant unless the entire sequence from DIBAL-H reduction to BF₃ complexation is run under a glovebox atmosphere holding O₂ < 5 ppm. Products are supplied as lyophilised research-grade fluorescent dyes with a certificate of analysis referencing ISO 13485:2016 for diagnostic reagent manufacture and are registered under EU REACH as a substance for laboratory use only. Terminal application vehicles include lateral flow immunochromatographic test strips, flow cytometry probes, and DNA sequencing laser dyes demanding photostability exceeding 10,000 excitation-emission cycles without significant bleaching.

Brominated Pyrrole-2-carboxylate Scaffolds and Downstream Acaricide Development

Structural optimisation of tetra-substituted pyrrole acaricides—active against mite strains resistant to mitochondrial complex I inhibitors—relies on selective bromination at the 4-position of ethyl 3,5-dimethyl-2-pyrrolecarboxylate. The reaction employs N-bromosuccinimide (NBS, 1.05 eq.) and a radical initiator, 2,2′-azobis(isobutyronitrile) (AIBN, 0.02 eq.), in anhydrous acetonitrile at reflux (82 °C). Critical to product purity is the dosing mode of AIBN: dissolving the initiator in a small volume of acetonitrile and adding it via syringe pump over 2 h suppresses the formation of local hot spots that would otherwise generate 4,5-dibromo and ring-oxidized species, dropping the isolated yield of ethyl 4-bromo-3,5-dimethyl-2-pyrrolecarboxylate from 78% to below 42%. On a 100 L scale the bromination is run in a double-jacketed glass-lined reactor with radial turbine agitation; post-reaction the succinimide by-product is filtered, the filtrate concentrated under vacuum at ≤50 °C, and the residue recrystallized from n-heptane to achieve >99% GC purity. This brominated intermediate is supplied to agrochemical formulators under a FAO/WHO pesticide specification self-certification package and must comply with EPA 40 CFR Part 158 toxicological data requirements for the technical active ingredient. Follow-on downstream processing converts the ester to the corresponding hydrazide or amide, which, after cyclisation with a suitable diketo ester, yields the active acaricide. The final formulated product is a 25% EC or a suspension concentrate applied at 0.3–0.5 L/ha for the control of Panonychus citri and Tetranychus urticae in citrus and pome fruit orchards; field trial reports document efficacy degradation if the bromo-intermediate purity falls below 98.5%, because the dibromo impurity leads to phytotoxicity symptoms on young leaf tissue when spray concentrations exceed 0.15% a.i.

When Copper Strip Corrosion Limits LPG Engine Oil Service Intervals

Copper-lead bearing corrosion in medium-speed stationary engines burning liquefied petroleum gas is mitigated by film-forming amine-free corrosion inhibitors derived from ethyl 3,5-dimethyl-2-pyrrolecarboxylate. The neat ester is converted to the corresponding N-(2-ethylhexyl)amide or morpholide by heating with 1.05 eq. of the primary or secondary amine in xylene at 130–140 °C for 6 h, with continuous distillation of the ethanol by-product to drive conversion past 97%. After vacuum stripping of solvent, the amide is blended into a pre-mixed additive package at a treat rate of 0.2–0.5 wt% of the finished oil formulation. The upper boundary of 0.5 wt% is determined by nitrile elastomer compatibility; immersion tests per DIN 53538 show volume swelling exceeding 8% at treat rates above 0.6 wt%, rendering the seal unsuitable for long-term service. The optimum dosage provides a 1a classification on the ASTM D130-18 copper strip test (3 h, 100 °C) and passes the synthetic seawater variant of ASTM D665-19 without interfacial rust. Pre-screening of the antiwear system is mandatory: zinc dialkyldithiophosphate (ZDDP) packages at typical 800–1000 ppm phosphorous compete with the pyrrole amide for absorption sites on cuprous surfaces, which can deteriorate the ASTM D130 rating from 1a to 2b unless the inhibitor treat rate is moved to the upper end of its range. Commercial finished lubricants formulated with this pyrrole-based inhibitor are released as ISO VG 220 industrial gear oils and ashless circulating oils for gas-engine compressors, supplied under a globally harmonised safety data sheet compliant with REACH Annex II and GHS Rev. 9.